Overdose deaths are falling in the United States, a sign of genuine progress. But President Trump’s claim that his administration has nearly stopped drugs from entering the country by sea confuses an interdiction statistic with an overdose-prevention strategy.
Trump has repeatedly asserted that his administration reduced maritime drug arrivals by 97 percent or more. That figure, however, merely compares drug seizures across two selected months. Because seizures measure what authorities intercept, not the unknown quantity traffickers successfully deliver, they cannot prove that nearly all maritime trafficking has stopped.
Nor does a decline in maritime seizures establish that the fentanyl supply has been eliminated. As the Drug Enforcement Administration notes, illicit fentanyl is primarily manufactured in clandestine laboratories and smuggled across the U.S.-Mexico border.
Yet the fundamental problem with Trump’s argument is broader: Even if his administration drastically curtailed the fentanyl supply, the overdose crisis would persist. Interdiction alters the drug market without removing the demand that sustains it.
Real physician voices, twice a week
Free, and one click to unsubscribe.
That distinction has been largely absent from American drug policy. While supply dictates availability, cost, and lethality, demand determines whether a market survives. Fentanyl’s extraordinary potency helps explain why so many die, but it does not explain why so many Americans seek chemical relief from physical pain, trauma, psychiatric illness, loneliness, housing insecurity, economic displacement, and despair. Fentanyl did not create those conditions, and eliminating it would not cure them.
When policymakers confuse the drug with the root causes of drug use, they repeatedly target the latest chemical while leaving the reasons people seek drugs untouched. The result is not a drop in demand, but a shift in consumption.
We have already conducted this national experiment. Opioid dispensing fell by more than half from its 2012 peak, yet overdose deaths continued to rise for years as the illicit market shifted from prescription opioids to heroin and then to fentanyl, increasingly laced with cocaine, methamphetamine, or sedatives.
The product changed. The source changed. The route changed. Only demand remained.
This does not mean supply reduction is futile. Disrupting cartels, precursor suppliers, money-laundering operations, and distribution networks can reduce availability and save lives. Supply matters enormously when a substance can kill in milligrams.
But supply suppression alone is inherently reactive. Close one route, and traffickers seek another. Make one drug scarce, and suppliers introduce a substitute. Remove a familiar product, and consumers may turn to something even less predictable and more dangerous. Demand does not vanish when supply contracts; it migrates toward what remains available.
In my book, Deconstructing Toxic Narratives: Data, Disparities, and a New Path Forward in the Opioid Crisis, I present research on geographic differences in drug mortality that reinforces this reality. Counties experiencing greater economic distress, housing strain, disability, and family disruption have reported significantly higher drug-related mortality. Social and economic environments shape stress, isolation, health behaviors, and vulnerability to substance use.
These are not peripheral “social issues” to be tackled after the drugs are removed. They form the risk environment that creates demand and hinders recovery.
The policy implication is straightforward: America must reduce both the lethality of the supply and the vulnerability that fuels demand. That requires enforcement against criminal organizations. But it also requires medications for opioid use disorder, naloxone, behavioral health care, recovery support, stable housing, and pathways to employment. It requires treating mental illness, trauma, and chronic pain rather than abandoning patients when regulations tighten. And it requires rebuilding the social connections and community institutions that protect people from isolation and help sustain long-term recovery.
While the recent decline in overdose deaths is welcome, it should not be misread. The Centers for Disease Control and Prevention estimates that 69,973 Americans died from drug overdoses in 2025, almost 14 percent fewer than in 2024, with the latest projections estimating 68,641 deaths for the 12 months ending in February 2026.
Yet even at these lower numbers, approximately 5,830 Americans die every month, nearly twice the number of lives lost on Sept. 11, 2001. A declining catastrophe remains a catastrophe.
The administration should also resist taking sole credit for this improvement. Overdose deaths began declining before Trump returned to office and before his current maritime campaign. Researchers have not identified a single explanation: Expanded naloxone access, addiction treatment, changes in fentanyl potency and availability, and local prevention programs may all play a role.
The responsible response is to determine what is working and strengthen it, not declare that destroying boats has solved the fentanyl crisis.
The most important question is not simply how fentanyl reaches the United States, but why so many Americans remain vulnerable to an illicit market they know is unpredictable and potentially fatal. Until policymakers answer that question, traffickers will adapt faster than enforcement. Fentanyl may eventually recede, but another drug or combination will fill the vacuum. Supply will mutate as long as demand persists.
America must disrupt dangerous drugs, but it cannot interdict its way out of an epidemic rooted in human suffering. The drug may change, but unless we address the demand for relief, the crisis will continue.
Lynn R. Webster is one of the world’s leading authorities on pain management, addiction medicine, and the complex interplay between public policy, misinformation, and human suffering. He is board-certified in anesthesiology, pain medicine, and addiction medicine, a past president of the American Academy of Pain Medicine, and a senior fellow at the Center for U.S. Policy.
He is the author of The Painful Truth: What Chronic Pain Is Really Like and Why It Matters to Each of Us, and coproducer of the PBS documentary of the same name. With Sarah Eichberg, PhD, he is coauthor of Deconstructing Toxic Narratives: Data, Disparities, and a New Path Forward in the Opioid Crisis (Springer Nature, May 28, 2026). A complete list of his titles is available on his books page, and he shares his work on LinkedIn, X, Facebook, and YouTube.
